Review Article

Detection of Herbal Combinations and Pharmacological Mechanisms of Clinical Prescriptions for Coronary Heart Disease Using Data Mining and Network Pharmacology

Siling Bi,1,2 Liang Xu,2 Shouqiang Chen,2 Shuai Bu,2 and Yunsheng Xu1,2

1Shandong University of Traditional Chinese Medicine, Jinan, China
2The Second Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan, China

Correspondence should be addressed to Yunsheng Xu; shandongxulaoshi@126.com

Received 21 April 2021; Revised 24 September 2021; Accepted 27 September 2021; Published 23 October 2021

Copyright © 2021 Siling Bi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Though widely used in the treatment of coronary heart disease (CHD), the mechanism of traditional Chinese medicine (TCM) is still unclear because of its complex prescription rules. This study prospectively collected 715 prescriptions of TCM for the treatment of CHD. The characteristics of TCM in prescriptions were described and analyzed, and the rules of prescriptions were analyzed by using association rules. Frequency statistics showed that the high-frequency herbs with a frequency of more than 60% were Gan-cao, Huang-qi, Dang-gui, Chuan-xiong, Yan-hu-suo, and San-qi. The high-frequency herb combinations were summarized by using association rules. By using the method of the “Top N groups” to excavate the empirical prescriptions, the basic prescriptions for treating CHD were summarized. We named the intersection herbs of the basic prescriptions and the high frequency herbs as the core herbal prescription. To explore the possible mechanisms underlying the anti-CHD effect of the core herbal prescription, the bioactive components of core herbal prescription and their targets were screened out by using network pharmacology. Molecular docking was performed between the bioactive components and core targets. A total of 28 potential active ingredients and 5 core targets were identified for the treatment of CHD. The enrichment analysis results indicated that the mechanism of action mainly involved neuroactive ligand-receptor interaction and calcium signaling pathway. The commonly used herbal pairs for CHD with qi deficiency and blood stasis syndrome were Huang-qi and Dang-gui. The mechanism of action of common herbal pairs was also studied by network pharmacology. This study summarized the prescription rule of TCM in the treatment of CHD and may provide a new idea for the treatment of CHD.

1. Introduction

Coronary heart disease (CHD) is a common heart disease and one of the leading causes of death worldwide [1, 2]. The World Health Organization (WHO) estimates that there are approximately 17.9 million deaths from cardiovascular diseases (https://www.who.int/health-topics/cardiovascular-diseases) and 7.4 million deaths from CHD worldwide each year [3]. As the world’s biggest killer, ischemic heart disease accounts for 16% of the world’s total deaths. Since 2000, the largest increase in deaths has been for this disease, rising by more than 2 million to 8.9 million deaths in 2019 (https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death).

TCM has a history of treating CHD and related diseases for thousands of years. It has unique advantages and remarkable clinical efficacy [4]. Due to its multicomponent characteristics, diseases can be treated through a variety of ways and targets [5, 6]. The large-scale clinical data are the core empirical knowledge source of TCM research [7]. Therefore, it is significant to study the experience of TCM in the treatment of CHD.

With modern computer technology shedding light on new ways for the innovation of TCM, quantitative research methods have attracted more and more attention. The adopted tools mainly consist of text mining, knowledge discovery, TCM database technology, data mining, and drug discovery through TCMSP [8]. The establishment of a
database which contains the relationships between TCM Symptoms, TCM herbs, and modern medicine (MM) symptoms integrates TCM with modern medicine at both the phenotypic and molecular levels [9]. Data mining can analyze the prescription patterns of TCM from clinical data and find the potential relationship between herbs and diseases [10]. It can evaluate the effect of interventions in a real clinical setting, which opens up a new path for researches of integrative herb in CHD [11].

In recent years, with the rapid development of bioinformatics, network pharmacology has become a new and powerful means to systematically reveal the principles and functions of complex biological systems [12, 13], and it has become an effective method to initially observe the effects of TCM at the system level and explore the potential pharmacological mechanism of TCM at the molecular level [13, 14].

Network pharmacology can form a complex interaction network based on target molecules, biological functions, and active compounds, which is in line with the natural characteristics of TCM prescriptions and can systematically clarify the mechanism of action of TCM prescriptions at the molecular level. It is expected to be a promising overall strategy for the research of TCM prescriptions [15–17].

This study aims to summarize the prescriptions and medication rules of TCM in the treatment of CHD and analyze its action pathway. Based on the website of prominent TCM doctors, this study conducted data mining on the proven records of the treatment of CHD by prominent TCM doctors. Our study may provide a reference for the clinical use of TCM in the treatment of CHD and the analysis of its potential mechanism of action.

2. Materials and Methods

2.1. Prescription Source. The cases were searched by using the website of prominent TCM doctors (https://121.42.193.121/) and setting the subject words as "coronary heart disease" and "western herb diagnosis." The time was set to be unlimited and the remaining conditions were set to default options. Finally, a total of 715 related cases were retrieved.

2.1.1. Inclusion Criteria. ① Clinical studies of TCM prescription in the treatment of CHD, including case analysis and control tests, were included. ② Cases with clinical medication experience of TCM and clear prescription composition were also included. ③ Patients with follow-up records should take the first prescription, and repeat prescriptions should be taken only once.

2.1.2. Exclusion Criteria. ① Cases with vague prescription symptoms and drug composition and/or no obvious therapeutic effect were excluded. ② Repeated cases were also excluded.

2.2. Prescription Screening and Standardization of TCM Terminology. Through the above setting of a series of conditions, a total of 715 prescriptions including 182 Chinese herbs were included. In order to ensure the rationality of data analysis and the accuracy of Chinese herbs, the names of herbs were standardized with reference to Chinese Pharmacopoeia 2015 Edition.

2.3. Data Statistics and Analysis

2.3.1. Frequency Statistics. The use frequency of herbs involved in the prescriptions included in the system was ranked in descending order, and the use frequency of the four qi, five flavors, and meridians of herbs were also ranked in descending order. The results were derived separately.

2.3.2. Analysis of Association Rules of Commonly Used Herbs in Basic Prescriptions. To generate association rules more effectively, the Apriori algorithm was used in data mining. In the analysis of medical records, it was possible to mine the association rules between Chinese herbs in the medical records of prominent TCM doctors and mine their high-frequency herb combinations. Then, the “Top N group” method was used to excavate experimental prescriptions and summarize the basic prescriptions for the treatment of CHD by prominent TCM doctors.

2.3.3. Study on Medication of Qi Deficiency and Blood Stasis Syndrome. According to TCM, qi deficiency and blood stasis are the fundamental and pathological basis of CHD. Clinical case review, cross-sectional investigation, and systematic literature review showed that qi deficiency and blood stasis syndrome are the most common clinical syndrome types of CHD and were the core syndromes throughout the occurrence and development of CHD [18]. The common herbal pairs for qi deficiency and blood stasis syndrome were found by association rules.

2.4. Analysis of Pharmacological Mechanism. With the aid of the Chinese medicine system pharmacology analysis platform (TC MSP, https://tcmspw.com/tcmsp.php), the chemical components of core herbal prescription were obtained. By using the compounds with bioavailability (OB) ≥30% and drug-like properties (DL) ≥0.18 as candidate active ingredients, the targets corresponding to the active ingredients were obtained by using the UniProt database (https://www.Uniprot.org/).

With "coronary heart disease" as the keyword, the protein targets of CHD were obtained through the GeneCards database. Then, using these targets as disease candidate targets, the gene names of the protein targets were queried in the UniProt database.

Wayne analysis was performed by Venny 2.1 software. The potential overlapping protein targets were obtained by intersecting the corresponding target of the drug candidate active ingredient with the single disease protein target. The protein network structure of potential intersection protein targets was visualized by Cytoscape 3.7.2 software.

The common targets of core herbal prescription and CHD were imported into the String protein interaction
Evidence-Based Complementary and Alternative Medicine

database (https://string-db.org/), and target protein–protein interaction (PPI) analysis was conducted. The whole node relationship information was exported, a target–target PPI network was constructed by using Cytoscape 3.7.2, and the core targets were screened out according to Degree.

In this study, DAVID software (https://david.ncifcrf.gov/) was used to perform GO enrichment analysis on the core target protein obtained after network merging. Statistical hypergeometric distribution was used to quantitatively evaluate protein populations. *P* value was used to reflect the significance of biological function of protein. Biological process, molecular function, and cellular component were selected. DAVID software was also used to carry out KEGG gene and signal pathway enrichment analysis on core protein target genes of drug component-disease intersection. Through the enrichment analysis of functional items, the main action pathways of core herbal prescription in the prevention and treatment of CHD were obtained.

2.5. Potential Active Ingredient-Target Molecular Docking Verification. Firstly, taking the mean parameters of "Degree" nodes in the component-target disease network model as reference conditions, the core active ingredients greater than the mean value were screened out. The MOL2 file of the relevant core active ingredients and 3D structure file of the key target protein (PDB format) were downloaded from TCMSP database and RSB database (https://www.rcsb.org), separately. Then, target protein files were imported into Chimera 1.14 software. Each protein molecule was minimally optimized and hydrodehydrated, and its primary ligand was removed. At the same time, the core active ingredients were introduced, and the treatment method was the same as above except for removing the mixture. Finally, after the performing of molecular docking by AutoDock-Vina 1.1.2 software, the obtained results were visualized.

3. Results

3.1. The Usage Frequency of Herbs. Among the 182 herbs, the top six high-frequency herbs were Gan-cao, Huang-qi, Dang-gui, Chuan-xiong, Yan-hu-suo, and Dang-gui. There were 27 herbs and 134 herbs that have been used more than 100 times and less than 50 times, respectively. The top 48 high-frequency herbs are shown in Table 1.

3.2. The Property, Taste, and Meridian Distribution of Herbs. The statistical results showed that among the four properties attributes, warm herbs were the most frequently used, accounting for 44.95%. Also, among the five flavor attributes, sweet was the most frequently used, accounting for 58.15%. The heart and liver meridians accounted for 56.75% and 49.64%, respectively (Table 2 and Figure 1).

3.3. Association Rules Analysis of High-Frequent Herbal Combination. The Apriori algorithm was used for the first scan, and the candidate set named C1 was obtained, that is, all herbs and their frequencies in the case of TCM for the treatment of CHD. Then, the minimum support was set to 0.3 to delete the candidate set with a frequency lower than 0.3, and finally the frequent set named L1 was obtained [19] (Table 3).

The candidate set named C2 was obtained from each combination of Chinese medicines in L1. Combinations with support less than 0.3 in candidate set named C2 were deleted to get L2, that is, the combination of two herbs (Table 4). L3, L4, and L5 were obtained by analogy and are shown in Tables 5–7, respectively.

3.4. The Core Groups and Basic Prescriptions. There were seven combinations of five Chinese herbs, involving seven Chinese herbs (Table 7). It was not difficult to find that the last six combinations all evolved from the first combination. From this, you can refer to the “Top N groups” method of mining empirical prescriptions [19]. That is, the corresponding minimum support was set to display the five-flavored herb combination, and they were arranged in the order of more-flavored herb combination to the less-flavored herb combination. Among the combinations of five flavors of herb, the combination with the highest frequency was the basic prescription for doctors to add or subtract. They were the motherboard for us to excavate the basic prescriptions. We selected the first “N” group in order, found out the Chinese herb that was different from the mother board as the daughter board and added it to the mother board. In this way, the basic prescriptions could be summarized. From this, we discovered that the basic prescriptions of TCM for the treatment of CHD were “Gan-cao, Huang-qi, Mai-dong, San-qi, Yan-hu-suo, Wu-wei-zi, and Dang-gui.”

3.5. Discovery of Commonly Used Herbal Pairs. The commonly used herbal pairs were obtained by setting the subject words as “coronary heart disease” and “western herb diagnosis” and the syndromes as “qi deficiency” and “blood stasis” and the minimum support to 0.6. Finally, a total of 372 related cases were retrieved. The commonly used herbal pairs for CHD with qi deficiency and blood stasis syndrome were Huang-qi and Dang-gui (Table 8).

3.6. Pharmacological Mechanisms of Core Herbal Prescription. The top six high-frequency herbs were Gan-cao, Huang-qi, Dang-gui, Chuan-xiong, Yan-hu-suo, and Dang-gui (Table 1). From the “Top N groups” method (Section 3.4), we discovered that the basic prescriptions of TCM for the treatment of CHD were “Gan-cao, Huang-qi, Mai-dong, San-qi, Yan-hu-suo, Wu-wei-zi, and Dang-gui.” We named the intersection herbs of the high-frequency herbs and the basic prescriptions as the core herbal prescription containing Gan-cao, Huang-qi, Yan-hu-suo, San-qi, and Dang-gui. To investigate the pharmacological mechanisms of the herbs involved in the core herbal prescription, we further obtained the ingredients of these five herbs from TCMSP with the filtering of pharmacokinetic parameters of OB ≥ 30% and DL ≥ 0.18. In total, we finally obtained 158
ingredients for these five herbs. In particular, 93 active ingredients of Gan-cao, 20 active ingredients of Huang-qi, 8 active ingredients of San-qi, 49 active ingredients of Yan-hu-suo, and 2 active ingredients of Dang-gui were obtained. Among them, quercetin was shared by Gan-cao, Huang-qi, Yan-hu-suo, and San-qi. Mairin, Jaranol, isorhamnetin, formononetin, Calycosin, and kaempferol were shared by Gan-cao and Huang-qi. Sitosterol was shared by Gan-cao and Yan-hu-suo. Beta-sitosterol was shared by Dang-gui and San-qi. Stigmasterol was shared by Dang-gui, Yan-hu-suo, and San-qi. Next, we obtained 148 drug targets for these five herbs referring to the TCMSP.

Table 1: Frequency distribution of high frequency herbs.

| No. | Herbs     | Frequency | Percentage |
|-----|-----------|-----------|------------|
| 1   | Gan-cao   | 543       | 75.94      |
| 2   | Huang-qi  | 536       | 74.97      |
| 3   | Dang-gui  | 525       | 73.43      |
| 4   | Chuan-xiong | 509    | 71.19      |
| 5   | Yan-hu-suo| 483       | 67.55      |
| 6   | San-qi    | 444       | 62.1       |
| 7   | Mai-dong  | 423       | 59.16      |
| 8   | Dan-shen  | 417       | 58.32      |
| 9   | Ye-ge-gen | 372       | 52.03      |
| 10  | Wu-wei-zhi| 361       | 50.49      |
| 11  | Huang-lian| 333       | 46.57      |
| 12  | Bing-pian | 322       | 45.03      |
| 13  | Suan-zao-ren| 286   | 40         |
| 14  | Huang-qin | 181       | 25.31      |
| 15  | Gui-zhi   | 176       | 24.62      |
| 16  | Gou-teng  | 175       | 24.84      |
| 17  | Fu-ling   | 170       | 23.78      |
| 18  | Ze-xie    | 167       | 23.36      |
| 19  | Shui-zhi  | 154       | 21.54      |
| 20  | Mu-xiang  | 148       | 20.7       |
| 21  | Bai-shao  | 140       | 19.58      |
| 22  | Ren-shen  | 119       | 16.64      |
| 23  | Yin-yang-huo | 110 | 15.38     |
| 24  | Sheng-di  | 105       | 14.69      |

Table 2: Frequency distribution of the property, taste, and meridian distribution.

| Project                | Property, taste, and meridian distribution | Frequency | Percentage |
|------------------------|-------------------------------------------|-----------|------------|
| Four properties        |                                           | 4742      | 44.95      |
|                        | Warm                                      | 3463      | 32.83      |
|                        | Cold                                      | 1729      | 16.39      |
|                        | Mild                                      | 440       | 4.17       |
|                        | Hot                                       | 175       | 1.66       |
| Five tastes            |                                           | 4234      | 40.14      |
|                        | Pungent                                   | 5066      | 48.02      |
|                        | Bitter                                    | 6134      | 58.15      |
|                        | Mild                                      | 369       | 3.5        |
|                        | Puckery                                   | 159       | 1.51       |
|                        | Sour                                      | 898       | 8.51       |
|                        | Salty                                     | 351       | 3.33       |
| Meridian distribution  |                                           | 5987      | 56.75      |
|                        | Heart                                     | 5236      | 49.64      |
|                        | Liver                                     | 4353      | 41.26      |
|                        | Spleen                                    | 3962      | 37.56      |
|                        | Lung                                      | 3679      | 34.88      |
|                        | Stomach                                   | 2037      | 19.31      |
|                        | Kidney                                    | 1420      | 13.46      |
|                        | Large Intestine                           | 1362      | 12.91      |
|                        | Gallbladder                               | 704       | 6.67       |
|                        | Pericardium                               | 684       | 6.48       |
|                        | Tri-jiao                                  | 108       | 1.02       |
|                        | Small Intestine                           | 35        | 0.33       |
database, which has 128 shared targets with the gene list of CHD (Figure 2).

The active ingredient and corresponding target information were imported into Cytoscape 3.7.2 software to draw the interaction network diagram, and the herb ingredient-target-disease core action network was extracted. The network topology analysis results showed that there were 321 network nodes, the network concentration degree was 0.372, the network density was 0.080, the network heterogeneity was 1.175, and the shortest path was 102720 (100%). The shape, size, and color of the diseases, herbs, targets, and ingredients were adjusted, and the target interaction relationship was visualized (Figure 3).

![Diagram showing network topology analysis results](image)

**Figure 1**: Frequency distribution of the property, taste, and meridian distribution.

**Table 3**: Frequent set $L_1$.

| Herbs     | Support | Herbs      | Support |
|-----------|---------|------------|---------|
| Gan-cao   | 0.76    | Dan-shen   | 0.58    |
| Huang-qi  | 0.75    | Ye-ge-gen  | 0.52    |
| Dang-gui  | 0.73    | Wu-wei-zi  | 0.51    |
| Chuan-xiong| 0.71 | Huang-lian | 0.46    |
| Yan-hu-suo| 0.68    | Bing-pian  | 0.45    |
| San-qi    | 0.62    | Suan-zao-ren| 0.40   |
| Mai-dong  | 0.59    |            |         |

The common target of core herbal prescription and CHD were imported into the String database. With *Homo sapiens* as the limited condition, protein interactions were obtained by using the multiple protein tool. The result involved a total of 128 nodes, 1321 edges, and an average node degree of 20.6, and the average local clustering coefficient was 0.552. As shown in Figure 4, the full node relationship information was exported and then imported into Cytoscape, and the core genes of PPI network were screened out according to the Degree value for visualization processing. As shown in Figure 5, the top five nodes with degree values were IL6, PTGS2, VEGFA, TNF, and MAPK1. These five key targets may play an important role in the treatment of CHD with core herbal prescription.
Enrichment analysis of 128 common targets of core herbal prescription and CHD was performed by DAVID software. 132 GO biological processes, 19 GO cell components, and 36 GO molecular functions were obtained. The biological processes included response to drug, adrenergic receptor signaling pathway, response to ethanol, response to hypoxia, and positive regulation of nitric oxide biosynthetic process. The cell components included extracellular space, plasma membrane, caveola, axon terminus, and integral component of plasma membrane. The molecular functions included enzyme binding, drug binding, steroid hormone receptor activity, protein homodimerization activity, RNA polymerase II transcription factor activity, and ligand-activated sequence-specific DNA binding. The top 15 of them were selected by Excel to carry out the three-in-one histogram visualization processing (Figure 6).

104 pathways were obtained by KEGG pathway analysis, including neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway, and TNF signaling pathway. The top 15 results of KEGG signal enrichment analysis were visualized by using the WeiShengXin (https://www.bioinformatics.com.cn/) online mapping website (Figure 7).

### 3.7. Results of Molecular Docking between Potential Active Ingredients and Key Target Proteins

Through the analysis of the "Degree" parameter in the ingredient-target-disease network model, 28 active compounds were screened out. Studies have shown that the lower the binding energy required for ligands for the binding of the ligand to receptors, the more stable the binding conformation. The results of this study showed that the binding energy between the target of core herbal prescription and CHD was negative. It is generally believed that the binding energy less than $-4.25 \text{kcal mol}^{-1}$ indicates that the ligand and the receptor have a certain binding activity. Binding energy less than $-5.0 \text{kcal mol}^{-1}$ indicates good binding activity while binding energy less than $-7.0 \text{kcal mol}^{-1}$ indicates strong binding activity [20]. The results of molecular docking are shown in Figure 8, and the docking mode of the compound with strong binding activity and the target protein molecule is shown in Figure 9.

### 3.8. Network Pharmacology Research on Herbal Pairs

According to the pharmacokinetic parameters of OB $\geq 30\%$ and DL $\geq 0.18$, 20 active ingredients of Huang-qi, 2 active ingredients of Dang-gui were obtained. There were 22 active ingredients in total (Table 9). Target prediction was carried out through the TCMSP database, and 133 effective targets of herbal pairs were obtained after correction with UniProt ID number.

-way analysis was carried out by Venny 2.1 software, and 117 intersection targets of herbs with CHD were screened out (Figure 10).

The full node relationship information was exported and then imported into Cytoscape, and the core genes of PPI network were screened out according to the Degree value for visualization processing. As shown in Figure 11, the top five nodes with degree values were IL6, VEGFA, TP53, TNF, and JUN.
| Combination of TCM (3) | Confidence | Combination of TCM (3) | Confidence |
|------------------------|------------|------------------------|------------|
| Dang-gui, Gan-cao, Huang-qi | 0.49 | Dang-gui, Dan-shen, Gan-cao | 0.36 |
| Gan-cao, Huang-qi, Mai-dong | 0.49 | Chuan-xiong, Dang-gui, San-qi | 0.35 |
| Huang-qi, San-qi, Yan-hu-suo | 0.48 | San-qi, Wu-wei-zi, Yan-hu-suo | 0.35 |
| Huang-qi, Mai-dong, Wu-wei-zi | 0.48 | Chuan-xiong, Gan-cao, San-qi | 0.35 |
| Gan-cao, San-qi, Yan-hu-suo | 0.46 | Bing-pian, San-qi, Yan-hu-suo | 0.35 |
| Gan-cao, Huang-qi, San-qi | 0.45 | Dan-shen, Huang-qi, Mai-dong | 0.34 |
| Gan-cao, Huang-qi, Yan-hu-suo | 0.45 | Chuan-xiong, Dang-gui, Ye-ge-gen | 0.34 |
| Dang-gui, Huang-qi, Mai-dong | 0.44 | Chuan-xiong, Gan-cao, Mai-dong | 0.34 |
| Chuan-xiong, Dang-gui, Gan-cao | 0.43 | Dang-gui, Mai-dong, Yan-hu-suo | 0.34 |
| Chuan-xiong, Gan-cao, Huang-qi | 0.43 | Dan-shen, San-qi, Yan-hu-suo | 0.33 |
| Chuan-xiong, Dang-gui, Huang-qi | 0.43 | Chuan-xiong, Mai-dong, Wu-wei-zi | 0.33 |
| Gan-cao, Huang-qi, Wu-wei-zi | 0.43 | Chuan-xiong, Dang-gui, Mai-dong | 0.33 |
| Dang-gui, Huang-qi, Yan-hu-suo | 0.42 | Dan-gao, San-qi, Wu-wei-zi | 0.33 |
| Dang-gui, San-qi, Yan-hu-suo | 0.42 | Dang-gui, Gan-cao, Wu-wei-zi | 0.33 |
| Huang-qi, Mai-dong, Yan-hu-suo | 0.42 | Gan-cao, Wu-wei-zi, Yan-hu-suo | 0.33 |
| Gan-cao, Mai-dong, Wu-wei-zi | 0.42 | Chuan-xiong, Huang-qi, Wu-wei-zi | 0.33 |
| Dang-gui, Huang-qi, San-qi | 0.41 | Dan-shen, Huang-qi, San-qi | 0.33 |
| Chuan-xiong, San-qi, Yan-hu-suo | 0.41 | Chuan-xiong, Gan-cao, Ye-ge-gen | 0.32 |
| Huang-qi, Mai-dong, San-qi | 0.41 | Chuan-xiong, Ye-ge-gen, Yan-hu-suo | 0.32 |
| Mai-dong, San-qi, Yan-hu-suo | 0.39 | Dan-shen, Huang-qi, Wu-wei-zi | 0.32 |
| Dang-gui, Gan-cao, Mai-dong | 0.39 | Chuan-xiong, Dang-gui, Dan-shen | 0.32 |
| Dan-gui, Gan-cao, Yan-hu-suo | 0.39 | Dan-shen, Huang-qi, Yan-hu-suo | 0.32 |
| Dang-gui, Huang-qi, Wu-wei-zi | 0.38 | Dan-shen, Gan-cao, Yan-hu-suo | 0.31 |
| Chuan-xiong, Huang-qi, Mai-dong | 0.38 | Chuan-xiong, Dan-shen, Gan-cao | 0.31 |
| Huang-qi, San-qi, Wu-wei-zi | 0.38 | Chuan-xiong, Dan-shen, Huang-qi | 0.31 |
| Chuan-xiong, Dang-gui, Yan-hu-suo | 0.38 | Chuan-xiong, Mai-dong, Gan-cao | 0.31 |
| Chuan-xiong, Huang-qi, Yan-hu-suo | 0.38 | Chuan-xiong, Mai-dong, Wu-wei-zi | 0.31 |
| Mai-dong, Wu-wei-zi, Yan-hu-suo | 0.38 | Chuan-xiong, Huang-qi, Ye-ge-gen | 0.31 |
| Gan-cao, Mai-dong, Yan-hu-suo | 0.38 | Dan-shen, Gan-cao, Mai-dong | 0.31 |
| Huang-qi, Wu-wei-zi, Yan-hu-suo | 0.38 | Dang-gui, Mai-dong, San-qi | 0.31 |
| Dang-gui, Mai-dong, Wu-wei-zi | 0.37 | San-qi, Ye-ge-gen, Yan-hu-suo | 0.31 |
| Mai-dong, San-qi, Wu-wei-zi | 0.37 | Gan-cao, Huang-qi, Ye-ge-gen | 0.31 |
| Chuan-xiong, Huang-qi, San-qi | 0.37 | Bing-pian, Huang-qi, Yan-hu-suo | 0.31 |
| Dang-gui, Dan-shen, Huang-qi | 0.37 | Dang-gui, Dan-shen, Yan-hu-suo | 0.31 |
| Dang-gui, San-qi, Wu-wei-zi | 0.37 | Bing-pian, Chuan-xiong, Yan-hu-suo | 0.31 |
| Gan-cao, San-qi, San-qi | 0.37 | Dang-gui, Dan-shen, Mai-dong | 0.31 |
| Dan-shen, Gan-cao, Huang-qi | 0.37 | Dan-shen, Mai-dong, Wu-wei-zi | 0.31 |

| Combination of TCM (4) | Confidence | Combination of TCM (4) | Confidence |
|------------------------|------------|------------------------|------------|
| Gan-cao, Huang-qi, Mai-dong, Wu-wei-zi | 0.41 | Dang-gui, Huang-qi, Mai-dong, Wu-wei-zi | 0.32 |
| Gan-cao, Huang-qi, San-qi, Yan-hu-suo | 0.4 | Chuan-xiong, Huang-qi, Mai-dong, Wu-wei-zi | 0.32 |
| Dang-gui, Gan-cao, Huang-qi, Mai-dong | 0.38 | Gan-cao, Mai-dong, San-qi, Wu-wei-zi | 0.32 |
| Huang-qi, Mai-dong, Wu-wei-zi, Yan-hu-suo | 0.37 | Gan-cao, Mai-dong, Wu-wei-zi, Yan-hu-suo | 0.32 |
| Gan-cao, Huang-qi, Mai-dong, Wu-wei-zi | 0.37 | Chuan-xiong, Gan-cao, Huang-qi, Mai-dong | 0.32 |
| Huang-qi, Mai-dong, San-qi, Yan-hu-suo | 0.37 | Chuan-xiong, Gan-cao, San-qi, Yan-hu-suo | 0.32 |
| Dang-gui, Huang-qi, San-qi, Yan-hu-suo | 0.37 | Chuan-xiong, Dang-gui, Wu-wei-zi, Yan-hu-suo | 0.32 |
| Gan-cao, Huang-qi, Mai-dong, Wu-wei-zi | 0.36 | Chuan-xiong, Dang-gui, San-qi, Yan-hu-suo | 0.32 |
| Huang-qi, Mai-dong, San-qi, Wu-wei-zi | 0.36 | Dang-gui, Huang-qi, San-qi, Wu-wei-zi | 0.32 |
| Chuan-xiong, Dang-gui, Gan-cao, Huang-qi | 0.35 | Chuan-xiong, Dang-gui, Huang-qi, San-qi | 0.31 |
| Mai-dong, San-qi, Wu-wei-zi, Yan-hu-suo | 0.34 | Dang-gui, Dan-shen, Gan-cao, Huang-qi | 0.31 |
| Huang-qi, San-qi, Wu-wei-zi, Yan-hu-suo | 0.34 | Chuan-xiong, Dang-gui, Huang-qi, Yan-hu-suo | 0.31 |
| Dang-gui, Gan-cao, Huang-qi, Yan-hu-suo | 0.34 | Dang-gui, Gan-cao, Mai-dong, Wu-wei-zi | 0.31 |
| Gan-cao, Huang-qi, San-qi, Wu-wei-zi | 0.33 | Dan-shen, Huang-qi, Mai-dong, Wu-wei-zi | 0.3 |
| Gan-cao, Huang-qi, Wu-wei-zi, Yan-hu-suo | 0.33 | Chuan-xiong, Huang-qi, Mai-dong, Yan-hu-suo | 0.3 |
| Dang-gui, Gan-cao, San-qi, Yan-hu-suo | 0.33 | Chuan-xiong, Gan-cao, San-qi, Wu-wei-zi | 0.3 |
| Chuan-xiong, Huang-qi, San-qi, Yan-hu-suo | 0.33 | Chuan-xiong, Dang-gui, Huang-qi, San-qi | 0.3 |
| Gan-cao, Mai-dong, San-qi, Yan-hu-suo | 0.33 | Dan-shen, Gan-cao, Huang-qi, Mai-dong | 0.3 |
| Dang-gui, Gan-cao, Huang-qi, San-qi | 0.33 | Gan-cao, San-qi, Wu-wei-zi, Yan-hu-suo | 0.3 |
The DAVID database was used to perform gene GO function and KEGG enrichment analysis on the intersection targets. GO analysis results showed that the main biological processes involved in the treatment of CHD with deficiency and blood stasis syndrome by Huang-qi and Dang-gui include response to drug, positive regulation of cell proliferation, extracellular space, caveola, enzyme binding, and steroid hormone receptor activity. The pathways involved include TNF signaling pathway, pathways in cancer, HIF-1 signaling pathway, Chagas disease (American trypanosomiasis), and calcium signaling pathway (Figure 12).

4. Discussion

CHD is thought to be a result of “congenital deficiency and postnatal malnutrition.” Deficiency in origin includes deficiency in qi, blood, yin, and yang; excess in superficiality includes qi stagnation, blood stasis, phlegm, and cold coagulation [21]. The previous epidemiological studies found that the core syndrome of patients with CHD is “Qi Deficiency and Phlegm-Blood Stasis” [22]. Contemporary famous old TCM doctors focus on certain core drugs when treating patients with CHD. Based on the top 3 most commonly used drug categories, the main therapeutic

| Combination of TCM (5)                     | Confidence |
|--------------------------------------------|------------|
| Huang-qi, Mai-dong, San-qi, Wu-wei-zi, Yan-hu-suo | 0.33       |
| Gan-cao, Huang-qi, Mai-dong, San-qi, Yan-hu-suo | 0.32       |
| Gan-cao, Huang-qi, Mai-dong, Wu-wei-zi, Yan-hu-suo | 0.32       |
| Gan-cao, Huang-qi, Mai-dong, San-qi, Wu-wei-zi | 0.32       |
| Dang-gui, Gan-cao, Huang-qi, Mai-dong, Wu-wei-zi | 0.31       |
| Dang-gui, Gan-cao, Huang-qi, San-qi, Yan-hu-suo | 0.30       |
| Gan-cao, Huang-qi, San-qi, Wu-wei-zi, Yan-hu-suo | 0.30       |

| Herbs                        | Confidence |
|------------------------------|------------|
| Huang-qi, Dang-gui           | 0.85       |
| Huang-qi, Gan-cao            | 0.82       |
| Huang-qi, Mai-dong           | 0.75       |
| Huang-qi, Yan-hu-suo         | 0.75       |
| Huang-qi, San-qi             | 0.74       |
| Huang-qi, Dan-shen           | 0.72       |
| Dang-gui, Gan-cao            | 0.72       |
| Yan-hu-suo, San-qi           | 0.69       |
| Huang-qi, Chuan-xiong        | 0.67       |
| Gan-cao, Mai-dong            | 0.67       |
| Huang-qi, Wu-wei-zi          | 0.67       |
| Dang-gui, Mai-dong           | 0.66       |
| Dang-gui, Yan-hu-suo         | 0.65       |
| Mai-dong, Wu-wei-zi          | 0.65       |
| Dang-gui, San-qi             | 0.64       |
| Gan-cao, Yan-hu-suo          | 0.64       |
| Gan-cao, San-qi              | 0.63       |
| Gan-cao, Dan-shen            | 0.62       |
| Dang-gui, Dan-shen           | 0.62       |
| Mai-dong, Yan-hu-suo         | 0.61       |
| Dang-gui, Chuan-xiong        | 0.60       |

Figure 2: Common targets for drugs and diseases.
Figure 3: Herb ingredient-target-disease network. Yellow represents the disease, purple represents the herb, blue represents the active ingredient of the herb, and green represents the related targets of CHD.

Figure 4: Interaction diagram between herbs and potential targets of CHD.
approaches used by these prestigious doctors included “Tonifying Qi, Activating Blood, and Eliminating Phlegm” [23].

This study collected 715 prescriptions including 182 Chinese herbs. The characteristics of TCM in prescriptions were described and analyzed, and the rules of prescriptions were analyzed by using association rules. Frequency statistics showed that the high frequency herbs with a frequency of more than 60% were Gan-cao, Huang-qi, Dang-gui, Chuan-xiong, Yan-hu-suo, and San-qi. At the same time, we also innovatively put forward the “Top N groups” empirical prescription mining method to summarize the basic prescriptions of TCM for the treatment of CHD with the aid of Apriori algorithm. We discovered that the basic prescriptions of TCM for the treatment of CHD were “Gan-cao, Huang-qi, Mai-dong, San-qi, Yan-hu-suo, Wu-wei-zi, and Dang-gui.” We named the intersection herbs of the basic prescriptions and the high-frequency herbs as the core herbal prescription. We found that Gan-cao, Huang-qi, Yan-hu-suo, San-qi, and Dang-gui were core herbal prescription. They can alleviate CHD from multiple angles. Gan-cao has the effects of tonifying the middle body and supplementing Qi [24]. Gan-cao has protective effects on the heart, and the hydrolysates of its main component glycyrrhizin is glycyrrhetinic acid, which has the effect of intervening the permeability transition of rat heart mitochondria [25]. The extract of Gan-cao can antagonize the cardiotoxicity induced by DOX and maintain the normal function of cardiac myocytes [26]. Huang-qi

Figure 5: PPI network diagram.
plays a role in improving metabolism, digestion, and endocrine function of the body [10]. Dang-gui nourishes blood and promotes blood circulation, Yan-hu-suo, and San-qi can promote blood circulation and relieve pain. Notoginsenoside R1 exerts cardioprotective effects against diabetic cardiomyopathy through its inhibition of oxidative stress and apoptosis [27, 28]. Pharmacodynamics studies showed that Panax notoginseng saponins (PNS) generated an obvious antiatherosclerosis action [29]. The application of core herbal prescription has confirmed that “Tonifying Qi, Nourishing Yin, Activating Blood, and Eliminating Phlegm” are the most commonly used therapeutic methods for patients with CHD [23]. Taking “Qi Deficiency” and “Blood Stasis” as the retrieval conditions, the commonly used drug pairs for CHD with qi deficiency and blood stasis syndrome were Huang-qi and Dang-gui. From this point of view, we can treat common CHD based on syndrome differentiation by using the core herbal prescription of TCM combined with the rules of medication. The application of data mining
technology enables the experience of TCM to be passed on.

Based on network pharmacology, this study screened the effective active ingredients and targets of core herbal prescription of TCM in the treatment of CHD. The intervention effect and mechanism of core herbal prescription on CHD were systematically studied. Through PPI network analysis, we found that the degree of value in the top five targets were IL6, PTGS2, VEGFA, TNF, and MAPK1. These five key targets may play an important role in the treatment of CHD with core herbal prescription.

IL-6 is independently associated with the risk of major adverse cardiovascular events, cardiovascular and all-cause mortality, myocardial infarction, heart failure, and cancer mortality in patients with stable CHD [30].

In the pathological process of CVD, cardiovascular disease stimulates the expression of inflammatory cytokines, leading to the upregulation of inflammatory mediators such as PTGS-2 [31, 32], which promotes PTGS-2 gene to encode COX-2 protein, and finally resulting in vascular calcification [33, 34].

VEGF is a homodimeric protein, including VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor (PLGF). VEGFA can induce acute, persistent and chronic leakage [35, 36], involving remodeling of junctions, induction of fenestrations, vesicle-vacuum organelles (VVOs), or transcellular transcytosis. Evidences showed that abnormal changes in the expression of certain genes in coronary artery disease play a crucial role in the pathogenesis of atherosclerosis [37, 38]. MicroRNAs are short noncoding RNAs with regulatory functions that are widely found in animals and plants [39]. Previous studies have found that miR-451 can inhibit liver tumor angiogenesis, suggesting that it may be involved in the formation of blood vessels [40]. Comprehensive bioinformatics prediction and dual-luciferase reporter gene detection showed that VEGFA is the target gene of miR-451b. MiR-451b may affect the PI3K-Akt-mTOR signaling pathway by altering the expression of VEGFA, thereby regulating the proliferation and apoptosis of HUVEC, and ultimately participating in the occurrence and development of CHD [41].

As a member of the TNF receptor family, the transmembrane death receptor induces apoptosis through an exogenous pathway [42]. TNF-α/TNFRI complex is involved in exogenous apoptosis of cardiomyocytes [43, 44]. Several typical apoptosis-stimulating fragment ligands (FasL)/FasR, TNF-α/TNFRI, TNF-associated apoptosis-inducing ligand (TRAIL)/DR4 and TRAIL/DR5, and their corresponding death receptors can
transmit death signals from cell surface to intracellular pathways through the death domain [42].

Atherosclerosis is a systemic degenerative inflammatory vascular disease and the primary underlying cause of CHD [45]. Based on the results of bioinformatics and cloning studies, researchers found that about 50 circulating miRNAs were associated with cardiovascular disease [46]. Many studies have proved that miRNAs (miR-1, miR133a, and miR-133b) play an important role in heart injury and myocardial infarction [47]. Mitogen-activated protein kinase 1 (MAPK1), as one of the mRNAs, is a candidate target gene for a variety of miRNAs [48]. Studies have shown that miR-197 leads to the silencing of MAPK1 gene by recognizing and specifically binding to the predicted site of the untranslated region of MAPK1 mRNA 3 [49]. Multiple studies have shown that MAPK1 plays an important role in the occurrence and development of atherosclerotic lesions [50–52]. A previous study has shown that everolimus-induced mTOR inhibition can selectively depletes macrophages in atherosclerotic plaques by autophagy, and mTOR pathway can stimulate macrophage autophagy and prevent atherosclerotic plaque formation [53–55]. Zhu et al. examined the interaction between miR-15b-5p and MAPK1, and the results showed that MAPK1 was a functional target for miR-15b-5p to regulate the progression of CAD. Long noncoding RNA (lncRNA) MALAT1 triggers the mTOR signaling pathway by regulating miR-15b-5p and MAPK1 [56].

132 GO biological processes, 19 GO cell components and 36 GO molecular functions were obtained by enrichment analysis. Biological processes included response to drug, adenylate cyclase-activating receptor signaling pathway, response to ethanol, response to hypoxia, and positive regulation of nitric oxide biosynthetic process. Cell components included extracellular space, plasma
Figure 9: Molecular docking stereogram (a) and molecular docking molecular diagram (b).
membrane, caveola, axon terminus, and integral component of plasma membrane. Molecular functions included enzyme binding, drug binding, steroid hormone receptor activity, RNA polymerase II transcription factor activity, and ligand-activated sequence-specific DNA binding.

A total of 104 pathways were obtained by KEGG pathway analysis, including neuroactive ligand-receptor interaction, calcium signaling pathway, pathways in cancer, cGMP-PKG signaling pathway, and TNF signaling pathway. Among these pathways, neuroactive receptor-ligand interaction has an influence on many organs and systems, including the nervous system, and may cause long-term dysfunction [57]. The calcium signaling pathway may influence the functions of nerves, muscles, and the heart through the release of neurotransmitters, muscular contraction, and cardiac conduction, respectively [58].

The results of molecular docking showed that the potential active ingredients of core herbal prescription have good binding properties with the intersection target protein of CHD. Based on this, we speculated that these components may play an important role in regulating the expression of CHD target proteins or interacting with these proteins.

Based on data mining, this research summarized the basic prescriptions and core herbal prescription of TCM in treating CHD. The network pharmacological research results found that core herbal prescription can achieve the anti-CHD effects through multicomponent, multitarget, and multisignal pathways. The results of molecular docking showed that the

| Mol ID     | Molecule name                          | OB (%) | DL   | Herb     |
|------------|----------------------------------------|--------|------|----------|
| MOL000211  | Mairin                                 | 55.37707338 | 0.7761 | Huang-qi |
| MOL000239  | Jaranol                                | 50.82881677 | 0.29148 | Huang-qi |
| MOL000296  | Hederagenin                            | 36.91390583 | 0.75072 | Huang-qi |
| MOL00033   | (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yl-octan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | 36.22847056 | 0.78288 | Huang-qi |
| MOL000354  | Isorhamnetin                           | 49.60437705 | 0.306 | Huang-qi |
| MOL000371  | 3,9-Di-O-methylnissolin                | 53.74152673 | 0.47573 | Huang-qi |
| MOL000374  | 5′-Hydroxyiso-muronulatol-2′,5′-di-O-glucoside | 41.71766574 | 0.69251 | Huang-qi |
| MOL000378  | 7-O-Methylisomuronulatol               | 74.8613752 | 0.29792 | Huang-qi |
| MOL000379  | 9,10-Dimethoxypterocarpan-3-O-β-D-glucoside | 36.73668801 | 0.9243 | Huang-qi |
| MOL000380  | (6aR,11aR)-9,10-Dimethoxy-6a,11a-dihydro-6H-benzofuran-3,2-c|chromen-3-ol| 64.25545452 | 0.42486 | Huang-qi |
| MOL000387  | Bifendate                              | 31.09782391 | 0.66553 | Huang-qi |
| MOL000392  | Formononetin                           | 69.67388061 | 0.21202 | Huang-qi |
| MOL000398  | Isoflavonone                           | 109.9866565 | 0.29572 | Huang-qi |
| MOL000417  | Calycosin                              | 47.75182783 | 0.24278 | Huang-qi |
| MOL000422  | Kaempferol                             | 41.88224954 | 0.24066 | Huang-qi |
| MOL000433  | FA                                     | 68.96043622 | 0.7057 | Huang-qi |
| MOL000438  | (3R)-3-(2-Hydroxy-3,4-dimethoxyphenyl)chroman-7-ol | 67.66747949 | 0.26479 | Huang-qi |
| MOL000439  | Isomuronulatol-7,2′-di-O-glucosiole    | 49.28105539 | 0.62065 | Huang-qi |
| MOL000442  | 1,7-Dihydroxy-3,9-dimethoxypterocarpene| 39.04541112 | 0.47943 | Huang-qi |
| MOL00098   | Quercetin                              | 46.43334812 | 0.27525 | Huang-qi |
| MOL00358   | Beta-sitosterol                         | 36.91390583 | 0.75123 | Huang-qi |
| MOL00449   | Stigmasterol                           | 43.82985158 | 0.75665 | Huang-qi |
Figure 10: Common targets for drug pairs and diseases.

Figure 11: PPI network diagram.
potential active ingredients of core herbal prescription had good binding properties with the intersection target protein of CHD, which confirmed that TCM treated CHD through multiple targets and pathways.

Although we have systematically studied the TCM treatment of CHD, there are several limitations of the study. Firstly, due to the limitation of data volume, the results of this study may be biased to some extent. Secondly, there are many methods of data mining for clinical prescriptions, involving association rule analysis, cluster analysis, artificial neural network, Bayesian algorithm, complex network, database method, and so on [59, 60]. However, our data mining method is relatively simple. Third, we only conducted network pharmacology research on the core herbal prescription, and the network pharmacology research on the successful prescriptions has not been done, for example, the relevant study of SheXiang XinTongNing (XTN) [61]. Related studies on the successful prescriptions need to be carried out in the future. Fourth, the relationships between diseases and syndromes are complex; one disease may express different syndromes [62]. Our research does not involve the distribution of syndromes. In future research, we will conduct research on the rules and mechanisms of the medication of syndromes. We will verify the effective targets and pathways through experiments to provide a strong basis for the development of new drugs.

5. Conclusions

A new prescription of CHD composed of Gan-cao, Huang-qi, San-qi, Yan-hu-suo, and Dang-gui has been extracted. The commonly used drug pairs for CHD with qi deficiency and blood stasis syndrome were Huang-qi and Dang-gui. The core herbal prescription mainly intervenes in neuroactive ligand-receptor interaction, calcium signaling pathway, pathways in cancer, cGMP-PKG signaling pathway, and TNF signaling pathway. Our results showed that the method and software used in this study can effectively analyze the mechanism and law of TCM prescription.

Data Availability

All the data used to support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors' Contributions

Yunsheng Xu and Shouqiang Chen designed the research. Siling Bi and Liang Xu collected the clinical data. Shuai Bu, and Liang Xu processed the data. Siling Bi and Liang Xu wrote the paper. All the authors approved the final edited version of the manuscript.

Acknowledgments

This study was financially supported by the Research on Inheritance and Innovation of Experience (Integration of Tao and Shu) of Illustrious Senior Traditional Chinese Herb Practitioners by Adopting Multiple Research Methods (no. 2018YFC1704100), Research on the Academic Viewpoints, Unique Diagnostic and Treatment Methods and Major Diseases Prevention and Treatment Experience of Illustrious Senior Traditional Chinese Medicine Practitioners in Central China (No. 2018YFC1704103) (1.47 million), and Taishan Scholars Project (no. ts201712097) (4 million).

Supplementary Materials

Table S1: the Pin-yin names and their corresponding Latin names are shown. (Supplementary Materials)

References

[1] X. Xu, H. Hu, and Y. Lin, “Differences in leukocyte telomere length between coronary heart disease and normal population: a multipopulation meta-analysis,” BioMed Research International, vol. 2019, Article ID 5046867, 2019.

[2] X. Yang, T. He, S. Han et al., “The role of traditional Chinese medicine in the regulation of oxidative stress in treating coronary heart disease,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 3231424, 2019.

[3] R. Chen, Y. Xiao, M. Chen et al., “A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials,” Bioscience Reports, vol. 38, no. 5, 2018.

[4] P. Hao, F. Jiang, J. Cheng, L. Ma, Y. Zhang, and Y. Zhao, “Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms,” Journal of the American College of Cardiology, vol. 69, no. 24, pp. 2952–2966, 2017.

[5] C. Wang, M. Niimi, T. Watanabe, Y. Wang, J. Liang, and J. Fan, “Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries,” Atherosclerosis, vol. 277, pp. 136–144, 2018.

[6] D. Yan, X. R. Xu, B. W. Yue, L. L. Zhao, S. H. Yan, and Y. L. Qian, “How to continue lipid-lowering therapy in patients with coronary heart disease and severe liver dysfunction?: a case report of plaque regression by a combination of Chinese and western medicine,” Medicine, vol. 98, no. 43, Article ID e17664, 2019.

[7] X. Zhou, S. Chen, B. Liu et al., “Development of traditional Chinese medicine clinical data warehouse for medical knowledge discovery and decision support,” Artificial Intelligence in Medicine, vol. 48, no. 2-3, pp. 139–152, 2010.

[8] X. Chu, B. Sun, Q. Huang, S. Peng, Y. Zhou, and Y. Zhang, “Quantitative knowledge presentation models of Traditional Chinese Medicine (TCM): a review,” Artificial Intelligence in Medicine, vol. 103, Article ID 101810, 2020.

[9] Y. Wu, F. Zhang, K. Yang et al., “SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping,” Nucleic Acids Research, vol. 47, no. D1, pp. D1110–D1117, 2019.

[10] C. Luo, H. Yu, T. Yang et al., “Data mining and systematic pharmacology to reveal the mechanisms of Traditional Chinese Medicine in recurrent respiratory tract infections’ treatment,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 8979713, 2020.

[11] Y. Feng, Y. Wang, F. Guo, and H. Xu, “Applications of data mining methods in the integrative medical studies of coronary heart disease: progress and prospect,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 791841, 2014.

[12] B. Boezio, K. Audouze, P. Ducrot, and O. Taboureau, “Network-based approaches in pharmacology,” Molecular Informatics, vol. 36, p. 10, 2017.

[13] H. Yuan, Q. Ma, H. Cui et al., “How can synergism of traditional medicines benefit from network pharmacology?” Molecules, vol. 22, p. 7, 2017.

[14] R. Zhang, X. Zhu, H. Bai, and K. Ning, “Network pharmacology databases for Traditional Chinese Medicine: review and assessment,” Frontiers in Pharmacology, vol. 10, p. 123, 2019.

[15] A. L. Hopkins, “Network pharmacology,” Nature Biotechnology, vol. 25, no. 10, pp. 1110–1111, 2007.

[16] S. Li, “Exploring traditional Chinese medicine by a novel therapeutic concept of network target,” Chinese Journal of Integrative Medicine, vol. 22, no. 9, pp. 647–652, 2016.

[17] G. Yu and J. Wang, “Exploring mechanisms of Panax notoginseng saponins in treating coronary heart disease by integrating gene interaction network and functional enrichment analysis,” Chinese Journal of Integrative Medicine, vol. 22, no. 8, pp. 589–596, 2016.

[18] W. Q. Zhang, S. C. Lu, and Y. P. Zhu, “Research status of syndromes of qi deficiency and blood stasis syndrome in coronary heart disease,” Journal of Traditional Chinese Medicine, vol. 62, no. 12, pp. 1092–1096, 2021.

[19] L. Xu, W. Bi, J. Hou, F. Yuan, and S. Chen, “Top N groups method of mining empirical prescriptions based on Apriori algorithm,” Guangming Traditional Chinese Medicine, vol. 30, no. 6, pp. 1181–1183, 2015.

[20] K. Y. Hsin, S. Ghosh, and H. Kitano, “Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology,” PLoS One, vol. 8, no. 12, Article ID e83922, 2013.

[21] Z. Gao, S. Li, Q. Shang et al., “Complex networks approach for analyzing the correlation of traditional Chinese medicine syndrome evolution and cardiovascular events in patients with stable coronary heart disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 824850, 2015.

[22] Y. Ren, M. Zhang, K. Chen et al., “Clinical and epidemiological Investigation of TCM syndromes of patients with coronary heart disease in China,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714517, 2012.

[23] Y. Chen, J. Wang, and T. Yang, “Herbal medicine prescribing patterns from contemporary famous old TCM doctors for treating coronary heart disease: an analysis based on data mining,” Medical Data Mining, vol. 4, no. 2, 2012.
Historical, biological, and clinical perspectives on inflammatory, metabolic, and atherosclerotic disease progression.

Evidence-Based Complementary and Alternative Medicine

[30] C. Held, H. D. White, R. A. H. Stewart et al., “Inflammatory biomarkers Interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial,” Journal of the American Heart Association, vol. 6, p. 10, 2017.

[31] L. Dou, M. Salle, C. Cerini et al., “The cardiovascular effect of the uremic solute indole-3 acetic acid,” Journal of the American Society of Nephrology, vol. 26, no. 4, pp. 876–887, 2015.

[32] Y. Ye, W. Bian, F. Fu, J. Hu, and H. Liu, “Selenoprotein S inhibits inflammation-induced vascular smooth muscle cell calcification,” Journal of Biological Inorganic Chemistry, vol. 23, no. 5, pp. 739–751, 2018.

[33] L. L. Demer and Y. Tintut, “Inflammatory, metabolic, and genetic mechanisms of vascular calcification,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 4, pp. 715–723, 2014.

[34] M. Agharazi, R. St-Louis, A. Gautier-Bastien et al., “Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification,” American Journal of Hypertension, vol. 28, no. 6, pp. 746–755, 2015.

[35] A. Wittmer, “Vascular endothelial growth factors and angiogenesis in eye disease,” Progress in Retinal and Eye Research, vol. 22, no. 1, pp. 1–29, 2003.

[36] J. A. Nagy, L. Benjaman, H. Zeng, A. M. Dvorak, and H. F. Dvorak, “Vascular permeability, vascular hyperpermeability and angiogenesis,” Angiogenesis, vol. 11, no. 2, pp. 109–119, 2008.

[37] A. A. Kondkar and K. K. Abu-Amero, “Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases,” BioMed Research International, vol. 2015, Article ID 821823, 2015.

[38] J. Ai, R. Zhang, Y. Li et al., “Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 73–77, 2010.

[39] V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, pp. 350–355, 2004.

[40] X. Liu, A. Zhang, J. Xiang, Y. Lv, and X. Zhang, “miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway,” Oncology Reports, vol. 36, no. 3, pp. 1383–1392, 2016.

[41] J. Lin, J. Jiang, R. Zhou, X. Li, and J. Ye, “MicroRNA-451b participates in coronary heart disease by targeting VEGFA,” Open Medicine, vol. 15, pp. 1–7, 2019.

[42] Y. Dong, H. Chen, J. Gao, Y. Liu, J. Li, and J. Wang, “Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease,” Journal of Molecular and Cellular Cardiology, vol. 136, pp. 27–41, 2019.

[43] K. A. Krown, M. T. Page, C. Nguyen et al., “Tumor necrosis factor α-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death,” Clinical Investigation, vol. 98, pp. 2854–2865, 1996.

[44] Y. Mondon, T. Kubota, T. Inoue et al., “Tumor necrosis factor-α is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 1, pp. H743–H753, 2007.

[45] R. S. Ripa, A. Kjaer, and B. Hesse, “Non-invasive imaging for subclinical coronary atherosclerosis in patients with peripheral artery disease,” Current Atherosclerosis Reports, vol. 16, no. 6, p. 415, 2014.

[46] M. Bhaskaran and M. Mohan, “MicroRNAs: history, bioinformatics, and their evolving role in animal development and disease,” Veterinary Pathology Online, vol. 51, no. 4, pp. 759–774, 2014.

[47] M. A. Chaudhry and R. A. Omaruddin, “Differential regulation of MicroRNA expression in irradiated and bystander cells,” Molecular Biology, vol. 46, no. 4, pp. 569–578, 2012.

[48] M. T. Rahman, K. Nakayama, M. Rahman et al., “KRAS and MAPK1 gene amplification in type II ovarian carcinomas,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13748–13762, 2013.

[49] H. L. Xiong, S. W. Zhou, Y. He, J. Li, and X. Yuan, “MicroRNA197 reverses the drug resistance of fluorouracil-induced SGC7901 cells by targeting mitogenactivated protein kinase 1,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5019–5025, 2015.

[50] Y. Chen, X. Duan, X. Yang et al., “Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 4, pp. 948–959, 2015.

[51] C. Banfi, M. Brioschi, S. Lento et al., “Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro,” Journal of Thrombosis and Haemostasis, vol. 9, no. 8, pp. 1608–1619, 2011.

[52] K. Bujold, D. Rhainds, C. Jossart, M. Febbraio, S. Marleau, and A. H. H. H. H., “Activation of mTOR modulates SREBP-2 to induce foam cell formation through
increased retinoblastoma protein phosphorylation,” *Cardiovascular Research*, vol. 100, no. 3, pp. 450–460, 2013.

[55] W. Martinet, S. Verheye, and G. R. De Meyer, “Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy,” *Autophagy*, vol. 3, no. 3, pp. 241–244, 2007.

[56] Y. Zhu, T. R. Yang, J. L. Duan, N. Mu, and T. Zhang, “MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway,” *Aging*, vol. 11, no. 4, 2019.

[57] J. Li, X. Qi, Y. Sun, Y. Zhang, and J. Chen, “Network pharmacology analysis on zhichan powder in the treatment of Parkinson’s disease,” *Combinatorial Chemistry and High Throughput Screening*, vol. 23, no. 1, pp. 28–40, 2020.

[58] S. C. Su, J. Seo, J. Q. Pan et al., “Regulation of N-type voltage-gated calcium channels and presynaptic function by cyclin-dependent kinase 5,” *Neuron*, vol. 75, no. 4, pp. 675–687, 2012.

[59] Z. Y. Wang, R. Wang, and R. N. She, “Research review of treatment of national TCM masters for angina pectoris of coronary heart disease based on data mining,” *Journal of Traditional Chinese Medicine Information*, vol. 27, no. 10, pp. 136–140, 2020.

[60] N. Wang, N. Du, Y. Peng et al., “Network patterns of herbal combinations in Traditional Chinese Clinical prescriptions,” *Frontiers in Pharmacology*, vol. 11, Article ID 590824, 2021.

[61] L. Y. Jia, G. Y. Cao, J. Li et al., “Investigating the pharmacological mechanisms of SheXiang XinTongNing against coronary heart disease based on network pharmacology and experimental evaluation,” *Frontiers in Pharmacology*, vol. 12, Article ID 698981, 2021.

[62] W. M. Xu, K. Yang, L. J. Jiang, J. Q. Hu, and X. Z. Zhou, “Integrated modules analysis to explore the molecular mechanisms of phlegm-stasis cementation syndrome with ischemic heart disease,” *Frontiers in Physiology*, vol. 9, p. 7, 2018.